港股异动 | 合景泰富集团(01813.HK)升逾5% 中期净利同比增1.75倍
格隆汇8月29日丨受业绩增长影响,合景泰富集团(01813.HK)大幅高开上涨,现涨5.04%,报6.67港元,暂成交3212万港元,最新总市值211.75亿港元。合景泰富集团(01813.HK)昨日公布,上半年公司实现毛利37.32亿元人民币(单位下同),同比增长246.2%;公司拥有人应占期内利润59.64亿元,同比增长174.6%;公司核心利润25.14亿元,同比增长28.1%。毛利增加主要由于2019年上半年总收入及已确认平均销售价格上升。东吴证券曾表示,公司2019上半年销售稳健增长,土地储备优质,潜在毛利水平高;投资性物业规模提升迅猛,未来租金进入收成期。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.